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Results: Neither clear tendency nor significance of the punch 
biopsy vs. HFUS depth determination is observed. Depth 
value differences with both modalities resulted patient 
dependent and then consequence of its uncertainty. 
Conceptually, HFUS should determine the macroscopic lesion 
(gross tumour volume or GTV) while punch biopsy is able to 
detect the microscopic extension (clinical target volume or 
CTV). Uncertainties of HFUS are difficult to address while 
punch biopsy is done just on a small lesion section, not 
necessarily the deepest one. 
 
 
Conclusions: According to the results, HFUS is less accurate 
at very shallow depths. Nodular cases present higher depth 
determination differences than superficial ones. In our 
clinical practice, we decided to prescribe at 3 mm depth 
when HFUS measurements give depth lesion values smaller 
than this value. 
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Purpose/Objective: Malignant obstructive jaundice (MOJ) 
due to extraepatic cholangiocarcinoma (ECC) is relieved by 
stenting via endoscopic retrograde cholangiopancreatography 
(ERCP) or percutaneous transhepatic cholangiography and 
biliary drainage (PTCD). Nevertheless, stent occlusion rates 
of 30-45% have been reported in literature due to tumour 
ingrowth or overgrowth. Brachytherapy seem to increase the 
patency of the stent. We retrospectively evaluated the 
feasibility of intraluminal brachytherapy (ILBT) and its role in 
preventing stent blockage. 
Materials and Methods: All patients unsuitable for surgery or 
inoperable because of poor general conditions affected by 
ECC with MOJ receiving PTCD or ERCP followed by self 
expanding metallic stent (SEMS) placement were enrolled. 
The clinical chart were reviewed retrospectively. After the 
bilirubin level reduction, HDR-Ir192 ILBT was performed by 
delivering the dose prescribed at 1 cm from central axis of 
the catheter. ILBT regimen included fractional doses of 5Gy 
given over 4-5 consecutive days for a total dose of 20-25Gy. A 
2D or 3D planning were expected . Stent patency duration 
was defined as duration between PTCD or ERCP procedures 
and detection of elevated bilirubin level (>50% of nadir value) 
after ILBT.  
Results: From November 2005 to August 2014, 14 patients 
were treated. Only 1 patient underwent external beam 
radiotherapy (total dose of 45 Gy in 25 fractions) combined 
with chemotherapy (gemcitabine 300 mg / m2 / iv / week) 
followed by ILBT (10 Gy / 2 fractions/ 2 days), while the 
remaining patients received ILBT alone with palliative intent 
(5Gy for 4 or 5 fractions). Six patients had a histologically 
confirmed diagnosis of adenocarcinoma, while the remaining 
8 patients had an instrumental diagnosis, nevertheless two 
consecutive biopsy of the tumour. Patient characteristics are 
as follows: 7 M and 7 F, median age at diagnosis 75 years 
(range 65-84), median performance status, assessed by the 
Karnofsky scale, 60% (range 50-90%). Twelve patients had 
Klatskin IV, 1 Klatskin IIIa and 1 Klatskin II. Main symptoms 
prior to brachytherapy were jaundice and abdominal pain, 
while, from a laboratory point of view, all patients had 
abnormalities of liver function tests typical of MOJ. All 
patients completed the scheduled treatment with mild acute 
toxicity; 3 patients developed cholangitis after ILBT, treated 
with antibiotic therapy. The stent remained patent until his 
death in 12 out of 14 patients (median 15.5 months, range 3-
96). At a median follow-up of 18.5 months (3-96 months) 11 
patients died due to disease progression, and only 3 are alive 
with stable disease.  
Conclusions: Intraluminal brachytherapy post PTCD or ERCP 
self expanding metallic stent (SEMS) placement seems to be 
feasible and effective in preventing stent occlusion. Our 
purpose is to confirm these results in a larger series. 
 
 
 
 
 
 
